Bempedoic Acid Now Available as First-in-Class LDL-C Lowering Therapy
Bempedoic acid is a first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL-C by inhibiting cholesterol synthesis in the liver.
Cardiovascular and Metabolic Disorders
Reviewing Evidence on the Screening, Diagnosis, and Care of Familial Hypercholesterolemia
Familial hypercholesterolemia is one of the most clinically relevant monogenic disorders contributing to the development of atherosclerotic cardiovascular disease.
Evolocumab Found Effective in Reducing Plasma LDL-C in Familial Hypercholesterolemia
Treatment with evolocumab was found to be effective in reducing plasma levels of low-density lipoprotein cholesterol in familial hypercholesterolemia.
Silent Myocardial Infarction Improves CVD Risk Discrimination in Diabetes
Inclusion of silent myocardial infarction in diabetes risk stratification improves risk discrimination over and beyond traditional factors.
Statin-Associated Risk for Intracerebral Hemorrhage in Patients With Prior Stroke
Treatment with statins is not associated with increased risk for ICH in patients with a history of stroke, and may even decrease the risk for ICH in some of these patients.
Addressing Metabolic Syndrome Risk in Shift Workers
Among other strategies, clinicians can suggest changes to lifestyle habits, encourage sleep hygiene, and prescribe pharmacologic interventions to combat risk for metabolic syndrome in shift workers.
Bariatric Surgery Linked to Lower Long-Term Risk for MI, Heart Failure, Mortality
For patients with obesity, bariatric surgery is associated with a lower long-term risk for major cardiovascular events and incident heart failure.
Machine Learning Predicts Noncalcified Coronary Burden in Psoriasis
Machine learning identifies factors related to obesity, dyslipidemia, and inflammation as predictors of noncalcified coronary burden in patients with psoriasis, a study finds.
Haptoglobin Genotype Affects CV Outcomes of Intensive Glucose-Lowering Therapy in T2D
intensive glucose-lowering therapy associated with a reduced risk for coronary heart disease in patients with type 2 diabetes with hp2-2 genotype.
Psoriasis in Adolescents Linked to Cardiometabolic Risk Factors
Early markers of cardiovascular and metabolic disease were elevated in adolescents with psoriasis, despite early disease.
Next post in Cardiovascular and Metabolic Disorders
